治験一覧
8,963 件中 4961〜4980 件を表示
難治性進行胃食道癌におけるレゴラフェニブの研究
A randomised phase III, double-blind, placebo-controlled trial with 2:1 (regorafenib : placebo)
潰瘍性大腸炎の成人患者を対象としたフィルゴチニブの長期継続試験
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative colitis (UC).
進行悪性腫瘍の成人患者におけるMAK683の安全性と有効性
The purpose of this Phase I/II study is to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and to evaluate the safety, antitumor activity and pharmacokinetic (PK) profile of MAK683 in patients with advanced malignancies such as Diffuse Large B cell Lymphoma (DLBCL), nasopharyngeal carcinoma (NPC) or other advanced solid tumors for whom no further effective standard treatment is available.
完全切除非小細胞肺癌（NSCLC）に対する術後補助療法MEDI4736の二重盲検プラセボ対照試験
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
フォメピゾール静脈内投与に関する特定薬物使用調査（全症例監視）
The objective of this survey is to evaluate the safety and efficacy of fomepizole intravenous infusion in Japanese patients with ethylene glycol and methanol poisonings in daily medical practice.
TAK-137の第1相単回および複数回投与試験
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of TAK-137 in healthy male subjects.
早期関節リウマチ患者におけるアバタセプトの効果
The purpose of this study is to determine if abatacept is effective in the treatment of early rheumatoid arthritis.
残存腎機能と骨粗鬆症治療の関係
The relationship between osteoporosis drugs and kidney damage is unclear. In this study, we plan to reveal relationship between osteoporosis drugs and kidney damage.
EGFRチロシンキナーゼ阻害剤未治療の非小細胞肺癌患者（EGFR変異を有する患者）におけるASP8273の有効性に関する研究
The purpose of this study is to determine the safety, the antitumor activity and the pharmacokinetics of ASP8273 in EGFR tyrosine kinase inhibitor (EGFR-TKI)-naïve patients with non-small cell lung cancer (NSCLC) harboring EGFR activating mutations.
慢性安定狭心症および高尿酸血症患者におけるフェブキソスタットの冠動脈プラーク量への影響
The purpose of this study is to investigate the effects of febuxostat on coronary plaque volume in patients with chronic stable angina and hyperuricemia.
FYU-981の反復投与第I相試験
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of 7-day-repeated doses of FYU-981 administered orally to healthy male adults once daily. Participants are randomized to placebo (n=3) or FYU-981 (n=6) in each step. After follow-up examination in the step of lower dose, the next dose is administered.
難治性全身性重症筋無力症におけるエクリズマブの安全性および有効性を評価するためのECU-MG-301延長試験
To evaluate the safety and efficacy of eculizumab in the treatment of refractory generalized myasthenia gravis (gMG) as an extension study for the participants who previously completed Study ECU-MG-301(NCT01997229).
進行性固形腫瘍を有する東アジア人患者における、アリセルチブ（MLN8237）と週1回投与のパクリタキセルの併用療法
The purpose of this study is to evaluate the safety and tolerability and determine the MTD to subsequently define an RP2D of alisertib in combination with weekly paclitaxel in East Asian participants with advanced solid tumors.
重症血友病A型またはB型（阻害因子の有無を問わない）患者を対象としたBAY 1093884の単回漸増投与および複数回投与試験
Investigate the safety, tolerability and pharmacokinetics of BAY1093884 after Intravenous (IV) and subcutaneous (SC) administration of increasing single doses and SC administration of multiple doses.
本態性高血圧症患者を対象としたTAK-536TCHの第III相長期試験
The purpose of this study is to evaluate the safety of long-term administration of TAK-536, amlodipine (AML), and hydrochlorothiazide (HCTZ) in participants with essential hypertension.
アルツハイマー病患者を対象としたMT-4666の安全性試験
The objective of this study is to evaluate the safety and efficacy of 2 fixed dose of MT-4666 administered once daily for 52 weeks with or without receiving a concomitant acetylcholinesterase inhibitors (AChEIs), in patients with mild to moderate Alzheimer's Disease (AD).
ジペプチジルペプチダーゼ-4（DPP-4）阻害薬またはナトリウム-グルコース共輸送体2型（SGLT2）阻害薬の代謝および心血管系への影響
Inhibition of dipeptidyl peptidase-4 (DPP-4) or sodium-glucose co-transporter type 2 (SGLT2) has been proposed as a therapeutic target for type 2 diabetes. However, how DPP-4 inhibitors or SGLT2 inhibitors exert protective actions for diabetic complications in addition to their glucose-lowering effects remains unknown.
胃腺癌または胃食道接合部腺癌患者におけるラムシルマブの有効性に関する研究
The main purpose of this study is to evaluate the effectiveness of S-1 and oxaliplatin with or without ramucirumab as first line therapy in participants with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
化学療法未治療の転移性大腸がんに対するベバシズマブ＋3剤併用療法
The purpose of this study is to evaluate the efficacy and safety of fluorouracil (5-FU), levofolinate calcium (l-LV), oxaliplatin (L-OHP) and irinotecan hydrochloride hydrate (CPT-11) (FOLFOXIRI) plus bevacizumab in untreated metastatic colorectal cancer patients who harbor Uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1) \*1/\*1, \*1/\*6 or \*1/\*28.
Oxymapを用いた網膜血管の酸素飽和度の測定
Retinal oximetry can be measured with newly developed Oxymap (Oxymap ehf, Reykjavik, Iceland). Briefly, the device simultaneously acquires digital images at two wavelengths and automatically tracks retinal vessels on both images. Retinal vessel oxygen saturation is estimated by spectrophotometric analysis of light reflected from retinal vessels and from the immediately surrounding retina. Oxygen saturation measurements are made on major temporal arteries and veins. Briefly, the first and second degree vessels are used, with the addition of third degree vessels in images where peripapillary haemorrhage prevented analysis close to the optic disc. Vessel segments chosen for analysis are used consistently for consecutive measurements in the same retina.